About: Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: “Adenovirus Vaccine Within an Adenovirus Vector”

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: “Adenovirus Vaccine Within an Adenovirus Vector” Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: “Adenovirus Vaccine Within an Adenovirus Vector”
Creator	Li, Min Zhang, Jing Wu, Jianguo Seto, Donald Feng, Liqiang Zhao, Shan Jing, Shuping Zeng, Zhiwei Yan, Yuqian Wu, • Zhang, • Ou, Junxian Guan, Wenyi Lan, Wendong
Source	PMC
abstract	Human adenoviruses (HAdVs) are highly contagious and result in large number of acute respiratory disease (ARD) cases with severe morbidity and mortality. Human adenovirus type 3 (HAdV-3) is the most common type that causes ARD outbreaks in Asia, Europe, and the Americas. However, there is currently no vaccine approved for its general use. The hexon protein contains the main neutralizing epitopes, provoking strong and lasting immunogenicity. In this study, a novel recombinant and attenuated adenovirus vaccine candidate against HAdV-3 was constructed based on a commercially-available replication-defective HAdV-5 gene therapy and vaccine vector. The entire HAdV-3 hexon gene was integrated into the E1 region of the vector by homologous recombination using a bacterial system. The resultant recombinants expressing the HAdV-3 hexon protein were rescued in AD293 cells, identified and characterized by RT-PCR, Western blots, indirect immunofluorescence, and electron microscopy. This potential vaccine candidate had a similar replicative efficacy as the wild-type HAdV-3 strain. However, and importantly, the vaccine strain had been rendered replication-defective and was incapable of replication in A549 cells after more than twenty-generation passages in AD293 cells. This represents a significant safety feature. The mice immunized both intranasally and intramuscularly by this vaccine candidate raised significant neutralizing antibodies against HAdV-3. Therefore, this recombinant, attenuated, and safe adenovirus vaccine is a promising HAdV-3 vaccine candidate. The strategy of using a clinically approved and replication-defective HAdV-5 vector provides a novel approach to develop universal adenovirus vaccine candidates against all the other types of adenoviruses causing ARDs and perhaps other adenovirus-associated diseases.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1007/s12250-020-00234-1
has license	no-cc
sha1sum (hex)	9583e76fc97c113e279d874e35a1073dd1201a29
schema:url	https://doi.org/10.1007/s12250-020-00234-1
resource representing a document's title	Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: “Adenovirus Vaccine Within an Adenovirus Vector”
has PubMed Central identifier	PMC7248191
schema:publication	Virol Sin
resource representing a document's body	covid:9583e76fc97c113e279d874e35a1073dd1201a29#body_text
is schema:about of	named entity 'NEUTRALIZING ANTIBODIES' named entity 'HOMOLOGOUS RECOMBINATION' named entity 'ADENOVIRUSES' named entity 'HUMAN ADENOVIRUS TYPE 3' named entity 'CAUSING' named entity 'morbidity' named entity 'recombinant' named entity 'A549' named entity 'gene' named entity 'recombinant' named entity 'adenovirus vaccine' named entity 'Asia' named entity 'RT-PCR' named entity 'vector' named entity 'immunogenicity' named entity 'ARD' named entity 'neutralizing antibodies' named entity 'Recombinant' named entity 'Adenovirus Vector' named entity 'chromogenic' named entity 'kDa' named entity 'ligation' named entity 'hexon' named entity 'avian influenza virus' named entity 'homologous recombination' named entity 'vaccines' named entity 'adenoviruses' named entity 'China' named entity 'primer pairs' named entity 'recombinant vaccine' named entity 'titer' named entity 'epitope' named entity 'sodium' named entity 'virus' named entity 'gene' named entity 'hexon' named entity 'hexon' named entity 'phosphor' named entity 'PCR' named entity 'Kirn' named entity 'antibody' named entity 'intranasally' named entity 'ampicillin' named entity 'adenoviruses' named entity 'mice' named entity 'vaccines' named entity 'ARD' named entity 'hexon' named entity 'pathogens' named entity 'genomic DNA' named entity 'hexon' named entity 'hexon' named entity 'A549' named entity 'E. coli' named entity 'vector' named entity 'infection' named entity 'SDS-PAGE' named entity 'infection' named entity 'antibody titer' named entity 'copy numbers' named entity 'plasmid' named entity 'Adenoviral Vector' named entity 'PCR' named entity 'transfection' named entity 'eukaryotic cells' named entity 'real-time PCR' named entity 'monomer' named entity 'neutralization test' named entity 'RNA' named entity 'vaccine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software